Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: Recent Advances
<p>Hepatocellular carcinoma (HCC) remains the third leading cause of cancer-related mortality worldwide. There were approximately 865000 new cases and 758000 new deaths from HCC globally in 2022, with a projected 77% increase in cases by 2050. Based on landmark clinical trials, such as IMbrave150, H...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2026
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/1237170 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: Recent Advances
- Gut Microbiota and Immune Checkpoint Inhibitors: A Synergistic Approach in Hepatocellular Carcinoma Therapy
- Introductory Chapter: Introduction to New Insights and Recent Progress in Immune Checkpoint Inhibitors
- Hepatocellular Carcinoma: Recent Advances in Curative Liver Resection
- Recent Advancements in Immunotherapy and Targeted Therapy in Hepatocellular Carcinoma
- Recent Advances in Systemic Therapy for Malignant Pleural Mesothelioma: Focus on Anti-Angiogenic Inhibitors and Immune Checkpoint Inhibitors
- Neoadjuvant Immune Checkpoint Inhibitors and Antibody-Drug Conjugates in Urothelial Carcinoma: Current Evidence and Future Perspectives